» Articles » PMID: 29973719

Species-specific Activity of Antibacterial Drug Combinations

Abstract

The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine. Drug combinations can help to fight multi-drug-resistant bacterial infections, yet they are largely unexplored and rarely used in clinics. Here we profile almost 3,000 dose-resolved combinations of antibiotics, human-targeted drugs and food additives in six strains from three Gram-negative pathogens-Escherichia coli, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa-to identify general principles for antibacterial drug combinations and understand their potential. Despite the phylogenetic relatedness of the three species, more than 70% of the drug-drug interactions that we detected are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between drugs that target different cellular processes, whereas synergies are more conserved and are enriched in drugs that target the same process. We provide mechanistic insights into this dichotomy and further dissect the interactions of the food additive vanillin. Finally, we demonstrate that several synergies are effective against multi-drug-resistant clinical isolates in vitro and during infections of the larvae of the greater wax moth Galleria mellonella, with one reverting resistance to the last-resort antibiotic colistin.

Citing Articles

Single-cell pathogen diagnostics for combating antibiotic resistance.

Li H, Hsieh K, Wong P, Mach K, Liao J, Wang T Nat Rev Methods Primers. 2025; 3.

PMID: 39917628 PMC: 11800871. DOI: 10.1038/s43586-022-00190-y.


One Earth-One Health (OE-OH): Antibacterial Effects of Plant Flavonoids in Combination with Clinical Antibiotics with Various Mechanisms.

Yuan G, Lian F, Yan Y, Wang Y, Zhang L, Zhu J Antibiotics (Basel). 2025; 14(1.

PMID: 39858294 PMC: 11761287. DOI: 10.3390/antibiotics14010008.


Drug combinations targeting antibiotic resistance.

Bognar B, Spohn R, Lazar V NPJ Antimicrob Resist. 2025; 2(1):29.

PMID: 39843924 PMC: 11721080. DOI: 10.1038/s44259-024-00047-2.


An overview of the use of non-titanium MXenes for photothermal therapy and their combinatorial approaches for cancer treatment.

Rahim F, Niyas K, Vivek R, Pathan S, Rasheed P Nanoscale Adv. 2025; 7(4):963-983.

PMID: 39830015 PMC: 11740912. DOI: 10.1039/d4na00931b.


Rethinking Biomedical Titanium Alloy Design: A Review of Challenges from Biological and Manufacturing Perspectives.

Rabbitt D, Villapun V, Carter L, Man K, Lowther M, OKelly P Adv Healthc Mater. 2024; 14(4):e2403129.

PMID: 39711273 PMC: 11804846. DOI: 10.1002/adhm.202403129.


References
1.
Piddock L, Jin Y, Ricci V, Asuquo A . Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 1999; 43(1):61-70. DOI: 10.1093/jac/43.1.61. View

2.
Saka K, Tadenuma M, Nakade S, Tanaka N, Sugawara H, Nishikawa K . A complete set of Escherichia coli open reading frames in mobile plasmids facilitating genetic studies. DNA Res. 2005; 12(1):63-8. DOI: 10.1093/dnares/12.1.63. View

3.
Ejim L, Farha M, Falconer S, Wildenhain J, Coombes B, Tyers M . Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol. 2011; 7(6):348-50. DOI: 10.1038/nchembio.559. View

4.
Mateus A, Gordon L, Wayne G, Almqvist H, Axelsson H, Seashore-Ludlow B . Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proc Natl Acad Sci U S A. 2017; 114(30):E6231-E6239. PMC: 5544291. DOI: 10.1073/pnas.1701848114. View

5.
Brown D . Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nat Rev Drug Discov. 2015; 14(12):821-32. DOI: 10.1038/nrd4675. View